Teva And Ignyta Cooperation On Oncology Tech

March 18, 2015 | The Israeli pharmaceutical company Teva Pharmaceutical Industries announced that it will sell four targeted oncology development programs to Ignyta. In exchange, Teva will have a six percent holding in the company responsible for developing precision oncology biotechnology. The companies have also entered into stock purchase agreements according to which Teva will purchase an additional 1.5 million shares in Ignyta for a 12 percent stake in total. Teva was founded in 1901 and is currently headed by President and CEO Erez Vigodman.